# US 2015/0104461 A1 · Anti-notch2 nrr antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104461 A1
- Document ID: US20150104461A1
- Status: Published application
- Kind: A1
- Application number: 14/298,488
- Filed: 2014-06-06
- Published: 2015-04-16
- Earliest claimed: 2013-10-11
- Assignees: Genentech, Inc.
- Applicants: Genentech, Inc.
- Inventors: Siebel W. Christian; Yan Wu
- Web page: https://patentgrep.com/patent/US20150104461A1

## CPC

- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61P 35/00: Antineoplastic agents
- C07K 16/30: from tumour cells
- C07K 16/3053: {Skin, nerves, brain}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides anti-Notch antibodies, and in particular, antibodies that bind Notch2 NRR, and methods of using the same.

## Claims

### Claim 1

A monoclonal antibody that binds to Notch2 negative regulatory region (NRR) and inhibits Notch2 activity, wherein the antibody binds both human and mouse Notch2 NRR with a Kd of ≦10 nM, and wherein the antibody comprises a heavy chain variable domain having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:20 and a light chain variable domain having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:22.

### Claim at position 2

2-4. (canceled)

### Claim 5 (depends on 1)

The antibody of claim 1, wherein the antibody comprises:
(a) a heavy chain hypervariable region (HVR-H) comprising the amino acid sequence of SEQ ID NO:3;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:4;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:5;
(d) a light chain hypervariable region (HVR-L) comprising the amino acid sequence of SEQ ID NO:10;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:14; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:19.

### Claim 6

(canceled)

### Claim 7 (depends on 5)

The antibody of claim 5, wherein the HVR-H1 comprises the amino acid sequence of SEQ ID NO:1, the HVR-L1 comprises the amino acid sequence of SEQ ID NO:6, the HVR-L2 comprises the amino acid sequence of SEQ ID NO:11, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO:15.

### Claim 8 (depends on 1)

The antibody of claim 1, wherein the HVR-H1 comprises the amino acid sequence of SEQ ID NO:1, the HVR-H2 comprises the amino acid sequence of SEQ ID NO:4; the HVR-H3 comprises the amino acid sequence of SEQ ID NO:5; the HVR-L1 comprises the amino acid sequence of SEQ ID NO:6, the HVR-L2 comprises the amino acid sequence of SEQ ID NO:11, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO:15.

### Claim at position 7

9-10. (canceled)

### Claim 11 (depends on 1)

The antibody of claim 1, further comprising at least one framework selected from a human VH Acceptor 2 framework and a human VL kappa subgroup I consensus framework.

### Claim at position 9

12-13. (canceled)

### Claim 14 (depends on 1)

The antibody of claim 1, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:20, and the light chain variable domain comprises the amino acid sequence of SEQ ID NO:22.

### Claim at position 11

15-18. (canceled)

### Claim 19 (depends on 1)

The antibody of claim 1, wherein the antibody is an antibody fragment selected from a Fab, Fab′-SH, Fv, scFv, or (Fab′)2 fragment.

### Claim 20 (depends on 1)

The antibody of claim 1, wherein the antibody is human, humanized, or chimeric.

### Claim 21 (depends on 1)

A method of inhibiting Notch2 activity, the method comprising exposing a cell that expresses Notch2 to the antibody of claim 1.

### Claim 22 (depends on 1)

A method of treating a disorder associated with increased expression or activity of Notch2, the method comprising administering to a subject in need thereof an effective amount of the antibody of claim 1.

### Claim 23 (depends on 22)

The method of claim 22, wherein the disorder associated with increased expression or activity of Notch 2 is a B-cell malignancy.

### Claim 24 (depends on 22)

The method of claim 22, wherein the disorder associated with increased expression or activity of Notch 2 is melanoma.
